zentalis board of directors

zentalis board of directors

In addition, Board member Dave Johnson has been appointed Chairman. restrict or inhibit any other user from using the boards. On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). Posted on 07/01/2020 72 . Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. He will report to Chief Executive Officer Dr. Kimberly Blackwell. The Board of Directors of Zentalis Pharmaceuticals. Dr. Blackwell has been an independent director of Zentalis since 2020. Board members at this company Cam S. Gallagher David M. Johnson Kimberly Blackwell As a member of Board of Directors at Zentalis Pharmaceuticals, Inc. , Cam S. Gallagher made $3,339,132 in total compensation. Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Companys founding. Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Companys founding. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Dr. NEW YORK & SAN DIEGO Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. 10835 Road to the Cure Suite 205 San Diego, CA 92121. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. USA, NY Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr. Enoch Kariuki, PharmD, to its Board of Directors. On May 10, 2022, | July 3, 2022 Notice to Search Firms/Third-Party Recruitment Agencies (Recruiters) The Human Resources team manages the recruitment and employment process for Zentalis Pharmaceuticals, Inc. (Zentalis) To protect the interest of all parties involved, Zentalis will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort.

Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis Scientific Advisory Board Medical Sector. Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors Explore New York business news Jan 9 2020 BoardMoves Mr. Johnson is a veteran biopharmaceutical and healthcare leader with more than 25 years of experience in developing drugs and Company profile for Zentalis Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. The Board of Directors of Zentalis Pharmaceuticals. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. We are excited to welcome David to our board as he brings his 357th out of 679 stocks (the "Company") sets high standards for the Company's employees, officers and directors. We are pleased to welcome Enoch to our Board of Directors, and believe his--Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical post or otherwise publish any content unrelated to the board or the board's topic. Matricelf is happy to announce that Adam Wollowick MD/MBA is joining its scientific advisory board. Zentalis provides equal employment opportunity to all employees and applicants without regard to an individuals protected status. See the breakdown of the total annual compensation for David M. Johnson for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Board of Directors in Zentalis Pharmaceuticals, Inc. For its 2020 fiscal year, Zentalis Pharmaceuticals, Inc., listed the following board members on its annual proxy statement to the SEC. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. For More Information. USA, NY Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr Kimberly Blackwell to its Board of Directors. Implicit in this philosophy is the importance of sound corporate governance. January 09, 2020 08:00 AM Eastern Standard Time. USA, NY Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Dr. Blackwell is a current member of Zentalis Board and previously served as Chief Medical Officer of Tempus Labs and held clinical development leadership roles at Eli Lilly and Company. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors /EIN News/ -- NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological Investors/Media Home Company Profile. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. Sun serves as Chief Executive Officer and a member of the board of directors of Zentera, the Companys joint venture in China and Kalyra Pharmaceuticals, Inc., or Kalyra, a small molecule drug discovery and On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). President and Director of Zentalis Pharmaceuticals. Item 5.02. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. For More Information. Melissa Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage cancer company, since September 2019. NEW YORK & SAN DIEGO Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors.Mr. On June 30, 2022, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") appointed Michael Miller to the Board, 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. On May 10, 2022, | July 3, 2022 Anthony Y. Dr. Kariuki is a highly accomplished finance He will report to Chief Executive Officer Dr. Kimberly Blackwell. Download PDF. 10835 Road to the Cure Suite 205 San Diego, CA 92121. She brings extensive experience as a senior financial executive in the life sciences industry. The average salary for Director of Philanthropy at companies like ZENTALIS PHARMACEUTICALS INC in the United States is $169,600 as of April 26, 2022, but the range typically falls between $144,400 and $199,700. re-post premium share chat posts on regular share chat. 1-212-433-3791 info@zentalis.com Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. Corporate Governance Overview. Press release content from Business Wire. The Pfizer Board Policies Ensuring ethical leadership Corporate Governance FAQs Learn more about our approach Contact Our Directors Email any of our Directors History; Careers. Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board. See the breakdown of the total annual compensation for Kimberly Blackwell for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors View detailed ZNTL.US description & address. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Non-employee members of the board of directors (the Board) of Zentalis Pharmaceuticals, Inc. (the Company) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this Program).This Program has been adopted under the Companys 2020 Incentive Award Plan (the Equity Plan) and shall be Mr.

I would like to thank Pat Machado for his contributions to the Board and Roivant over the past six years . Pharmaceutical Preparations Industry.

Comments are closed.